Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ijpharm.2012.08.038
DC FieldValue
dc.titleVitamin e TPGS prodrug micelles for hydrophilic drug delivery with neuroprotective effects
dc.contributor.authorMi, Y.
dc.contributor.authorZhao, J.
dc.contributor.authorFeng, S.-S.
dc.date.accessioned2014-06-17T07:51:18Z
dc.date.available2014-06-17T07:51:18Z
dc.date.issued2012-11-15
dc.identifier.citationMi, Y., Zhao, J., Feng, S.-S. (2012-11-15). Vitamin e TPGS prodrug micelles for hydrophilic drug delivery with neuroprotective effects. International Journal of Pharmaceutics 438 (1-2) : 98-106. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ijpharm.2012.08.038
dc.identifier.issn03785173
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/64786
dc.description.abstractDouble emulsion has been used most often in formulation of hydrophilic drugs by nanoparticles of biodegradable polymers, which has disadvantages such as low drug loading and low drug encapsulation efficiency due to the drug loss in the process. The drug release may be too fast for sustained chemotherapy. We developed in this research a d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) prodrug micelle system with cisplatin as a model hydrophilic drug. We demonstrated that such a system can successfully deliver the model hydrophilic drug with a low critical micelle concentration (CMC) of only 5.01 mg/L, a high drug load of 4.95% (w/w) and a pH-responsive drug release kinetics and higher cellular uptake in comparison with the original drug and the TPGS-cisplatin prodrug itself. The cell viability experiment showed great enhancement of the cisplatin chemotherapy, which is demonstrated by the IC50 value reduced from 3.95, 0.98, 0.19 for cisplatin to 1.36, 0.51, 0.08 μg/mL for the TPGS prodrug micelle formulation after 24, 48, 72 h culture with the HepG2 hepatocarcinoma cells, respectively. Furthermore, such a TPGS prodrug micellar formulation showed significant neuroprotective effects for the cisplatin chemotherapy, which is demonstrated by the greatly increased IC50 value for the SH-SY5Y neuroblast-like cells in comparison between cisplatin and the TPGS prodrug micelle formulation. The TPGS prodrug micelles can also be generalized to become a new strategy for codelivery of hydrophilic and hydrophobic drugs and/or imaging agents. © 2012 Elsevier B.V. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.ijpharm.2012.08.038
dc.sourceScopus
dc.subjectAnti-cancer drugs
dc.subjectBiodegradable polymers
dc.subjectCancer nanotechnology
dc.subjectDrug formulation
dc.subjectNanomedicine
dc.typeArticle
dc.contributor.departmentCHEMICAL & BIOMOLECULAR ENGINEERING
dc.description.doi10.1016/j.ijpharm.2012.08.038
dc.description.sourcetitleInternational Journal of Pharmaceutics
dc.description.volume438
dc.description.issue1-2
dc.description.page98-106
dc.description.codenIJPHD
dc.identifier.isiut000310763700011
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.